Literature DB >> 19214380

Widely varying TNF-alpha levels in patients with myasthenia gravis.

Jin Soo Lee1, In Soo Joo, Jung Im Seok.   

Abstract

Animal studies have indicated an important role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of myasthenia gravis (MG), and trials of monoclonal antibodies that block TNF-alpha have shown clinical improvement. However, before a TNF-alpha blocking agent is proposed for treatment of MG, whether serum TNF-alpha level correlates with the patient's condition should be confirmed. Therefore, we evaluated the relationship between the serum TNF-alpha level and clinical factors, including the quantitative MG score and the anti-acetylcholine receptor antibody level, in 33 MG patients. TNF-alpha levels ranged from 0.44 to 3.63 pg/mL and did not correlate with clinical factors. Overall, we found that serum TNF-alpha levels varied greatly among MG patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19214380     DOI： 10.1007/s10072-009-0023-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  11 in total

1.  Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis.

Authors:  Rui-Sheng Duan; Hua-Bing Wang; Jian-She Yang; Bernie Scallon; Hans Link; Bao-Guo Xiao
Journal:  J Autoimmun       Date:  2002-12       Impact factor: 7.094

2.  A clinical and immunological study of a myasthenia gravis patient treated with infliximab.

Authors:  M Kakoulidou; S Bjelak; R Pirskanen; A K Lefvert
Journal:  Acta Neurol Scand       Date:  2007-04       Impact factor: 3.209

3.  Cytokines and the pathogenesis of myasthenia gravis.

Authors:  G X Zhang; V Navikas; H Link
Journal:  Muscle Nerve       Date:  1997-05       Impact factor: 3.217

Review 4.  Myasthenia gravis.

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1994-06-23       Impact factor: 91.245

5.  Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment.

Authors:  Erdem Tüzün; Matthew N Meriggioli; Julie Rowin; Huan Yang; Premkumar Christadoss
Journal:  J Autoimmun       Date:  2005-05       Impact factor: 7.094

6.  Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein.

Authors:  Premkumar Christadoss; Elzbieta Goluszko
Journal:  J Neuroimmunol       Date:  2002-01       Impact factor: 3.478

7.  Etanercept treatment in corticosteroid-dependent myasthenia gravis.

Authors:  J Rowin; M N Meriggioli; E Tüzün; S Leurgans; P Christadoss
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

8.  Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis.

Authors:  R E Ahlberg; R Pirskanen; A K Lefvert
Journal:  Clin Immunol Immunopathol       Date:  1991-07

9.  Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.

Authors:  R S Tindall; J A Rollins; J T Phillips; R G Greenlee; L Wells; G Belendiuk
Journal:  N Engl J Med       Date:  1987-03-19       Impact factor: 91.245

10.  Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

Authors:  U A Besinger; K V Toyka; M Hömberg; K Heininger; R Hohlfeld; A Fateh-Moghadam
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910
View more
  3 in total

Review 1.  Adalimumab-induced myasthenia gravis: case-based review.

Authors:  Eleftherios Pelechas; Tereza Memi; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2020-04-22       Impact factor: 2.631

2.  Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

Authors:  H-W Yang; P Lei; Y-C Xie; Z-L Han; D Li; S-H Wang; Z-L Sun
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

3.  Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.

Authors:  Shuang Li; Yuze Cao; Lei Li; Huixue Zhang; Xiaoyu Lu; Chunrui Bo; Xiaotong Kong; Zhaojun Liu; Lixia Chen; Peifang Liu; Yang Jiao; Jianjian Wang; Shangwei Ning; Lihua Wang
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.